Comparative in vitro activity of the new oral macrolide azithromycin.
The in vitro activity of the new oral macrolide azithromycin was compared with that of erythromycin against gram-positive and gram-negative aerobic and anaerobic bacteria. Ninety percent of hemolytic streptococci groups A and B, and Streptococcus pneumoniae were inhibited by 0.5 microgram/ml. Activity of azithromycin was similar to that of erythromycin; erythromycin-resistant staphylococci and streptococci were not inhibited. Azithromycin was more active than erythromycin against Haemophilus influenzae (MIC90 1 microgram/ml) and Neisseria gonorrhoeae. It inhibited Campylobacter spp. and Pasteurella multocida, and had an MIC50 of 8 micrograms/ml for Escherichia coli, Salmonella spp., Shigella spp. and Yersinia enterocolitica compared to an erythromycin value of greater than 64 micrograms/ml.